Biosimilar of Remicade Works in Ankylosing Spondylitis

Biosimilar of Remicade Works in Ankylosing Spondylitis

CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found. At week 54 of treatment, 67% of patients receiving CT-P13 (Remsima, Inflectra) had …

(Visited 4 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.